Serial #79108413
LIVE

Serial Number

79108413

Owner

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

Filing Date

Jan 3, 2012

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79108413 Trademark

Serial Number: 79108413 • Registration: 4311029

Serial #79108413 is a trademark filed by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. on January 3, 2012. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (10 trademarks)

37F, Main Tower, Lvjing Plaza,
Futian Dist. Shenzhen 518040 , CN

Entity Type: 99

Trademark Details

Filing Date

January 3, 2012

Registration Date

April 2, 2013

Published for Opposition

January 15, 2013

Cancellation Date

January 4, 2022

Goods & Services

Medicines for human purpose, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Pharmaceutical preparations, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Chemico-pharmaceutical preparations, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; Capsules for pharmaceutical purposes, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; Raw material drug, namely, active pharmaceutical ingredients which are used for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system,digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; Chinese medicine nostrum, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Biochemical medicines, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Dietetic substances adapted for medical use, beverages or food which are used for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Additives to fodder for medical use; Medicines for veterinary purposes, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system,digestive system and endocrine system, for the treatment of infective diseases,for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases for use in veterinary

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Jul 23, 2022 DENC
DEATH OF INTERNATIONAL REGISTRATION
Jul 23, 2022 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Sep 12, 2020 INNT
GENERIC MADRID TRANSACTION SENT TO IB
Aug 16, 2020 XXSS
GENERIC MADRID TRANSACTION CREATED
Aug 15, 2020 XXCR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jul 8, 2020 INTR
CANCELLED SECTION 71
Nov 8, 2019 C71T
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Oct 8, 2019 CORN
CORRECTION TRANSACTION RECEIVED FROM IB
Jul 5, 2019 CRCV
NEW REPRESENTATIVE AT IB RECEIVED
Jul 4, 2019 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Dec 7, 2018 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Aug 7, 2014 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 20, 2013 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 3, 2013 FICS
FINAL DISPOSITION PROCESSED
Jul 3, 2013 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 2, 2013 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 2, 2013 R.PR
NOTIFICATION PROCESSED BY IB
Feb 20, 2013 GPNX
PUBLISHED FOR OPPOSITION
Jan 15, 2013 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 26, 2012 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 26, 2012 OP2R
NOTICE OF PUBLICATION
Dec 26, 2012 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Dec 10, 2012 PREV
ASSIGNED TO LIE
Dec 10, 2012 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 26, 2012 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 31, 2012 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 30, 2012 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 30, 2012 TROA
REFUSAL PROCESSED BY IB
Jul 1, 2012 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 8, 2012 RFCS
REFUSAL PROCESSED BY MPU
Jun 8, 2012 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 8, 2012 RFCR
NON-FINAL ACTION WRITTEN
Jun 7, 2012 CNRT
ASSIGNED TO EXAMINER
Apr 6, 2012 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 14, 2012 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 10, 2012 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 9, 2012 REPR